基于碎片的发现和MSC778的结构导向优化,这是第一个强效,选择性和口服生物可用的FEN1抑制剂
Sam E Mann1, Julien Lefranc2, Omar Alkhatib1
1Artios Pharma Ltd., B940, Babraham Research Campus, Cambridge CB22 3FH, U.K.
Journal of medicinal chemistry
|September 17, 2025
概括
研究人员发现MSC778,是一种强效和选择性的Flap内核酶1 (FEN1) 抑制剂. 这种新的候选药物显示出治疗BRCA突变癌症的前景,通过选择性杀死癌细胞和增强现有疗法.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 内核酶1 (FEN1) 是DNA修复途径中的一个关键酶.
- FEN1是BRCA突变癌症的治疗标,但现有的抑制剂具有局限性.
- 需要新的药理学工具来研究FEN1生物学.
研究的目的:
- 发现和描述新型,强效和选择性FEN1抑制剂.
- 开发用于FEN1向癌症治疗的先进药理工具.
- 探索FEN1抑制在BRCA缺陷癌症中的治疗潜力.
主要方法:
- 金属化碎片选.金属化碎片的选.
- 基于结构的药物设计和优化.
- 在BRCA2缺陷模型中的体外和体内疗效研究.
主要成果:
- 识别MSC778,这是第一个强效,选择性和口服生物可用FEN1抑制剂.
- MSC778可以选择性地消除缺乏BRCA2的癌细胞.
- 在体内,MSC778强化了PARP抑制剂 (PARPi) 尼拉帕里布,在BRCA2KO异种移植模型中诱导瘤静止.
结论:
- MSC778代表了FEN1向癌症治疗的重大进展.
- 这一发现突显了针对癌症治疗的核酶的潜力.
- 这种方法为开发用于BRCA突变癌症的新疗法提供了有希望的策略.
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Drug Discovery: Overview
11.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.1K


